Akero’s 96-Week Fibrosis Data Sparkle In MASH

 
• By Joseph Haas
  
Liver health
Akero shows significant fibrosis reduction in 96-week Phase IIb data • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D